The Effect of Esmolol on Clinical Prognosis of Patients With Severe Sepsis

Fujian Provincial Hospital151 enrolled

Overview

The purpose of this study was to investigate the effect of esmolol on hemodynamic parameters,tissue perfusion and the clinical prognosis of patients with severe sepsis

enrollment:151 patients Inclusion criteria: (1) age \> 18 years; (2) severe sepsis (acute organ dysfunction secondary to infection )diagnosis according to Campaign to Save Septic Patients: 2008 Treatment Guidelines for Severe Sepsis and Septic Shock, who (3) mechanical ventilation via endotracheal intubation with a tidal volume of 6 mL/kg; and (4) satisfactory sedation and analgesic treatment, with HR \> 100 bpm.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

151

Conditions

Severe Sepsis

Interventions

EsmololDRUG

patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm \< HR \< 100 bpm within 72 hours). Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.

natural salineDRUG

Control group also received natural saline via a micro pump,

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age \> 18 years; * severe sepsis (acute organ dysfunction secondary to infection )diagnosis according to Campaign to Save Septic Patients: 2008 Treatment Guidelines for Severe Sepsis and Septic Shock, * mechanical ventilation via endotracheal intubation with a tidal volume of 6 mL/kg; * satisfactory sedation and analgesic treatment, with HR \> 100 bpm. Exclusion Criteria: * pre-existing cardiac dysfunction, valvular heart disease, high-degree atrioventricular block; * acute or chronic pulmonary heart disease; * a history of serious asthma; * chronic renal insufficiency; * cancer, autoimmune diseases, or contraindications for placement of deep venous catheter; * insulin-dependent diabetes.

Outcomes

Primary Outcomes

The survival time of patients more than 28 days is defined as survival. The survival time of patients less than 28 days is defined as death.

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.